USPTO Patent Application: Sustained Transgene Expression of Modified ERT2 Peptide Fusion

The USPTO has published a patent application (US20260083859A1) detailing a novel fusion polypeptide for sustained transgene expression. The application, filed by inventors from various institutions, describes targeting constructs for inducible cell death systems using modified estrogen receptor ligand binding domains.

USPTO Patent Application: Antibody Drug Conjugate Comprising NMT Inhibitor

The USPTO has published a new patent application (US20260083858A1) related to antibody drug conjugates (ADCs) that comprise an NMT inhibitor conjugated to an antibody via a linker. The application details the inventors and abstract of the invention.

USPTO Patent Application for Anti-PD-1 Antibody-IL-2 Immunoconjugate Formulations

The USPTO has published a new patent application (US20260083857A1) for anti-PD-1 antibody-IL-2 immunoconjugate formulations. The application details stable pharmaceutical formulations comprising anti-human PD-1 antibody-modified human interleukin-2 immunoconjugates.

USPTO Patent Application: Thiazolidine Linkers for Protein-Drug Conjugates

The USPTO has published a new patent application (US20260083856A1) detailing thiazolidine linkers for protein-drug conjugates and their uses in treating diseases. The application was filed on September 11, 2025, and is scheduled for publication on March 26, 2026.

USPTO Patent Application for Immunoconjugates

The USPTO has published a new patent application, US20260083855A1, filed by Hoffmann-La Roche Inc. The application relates to immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. This filing is part of the standard patent application process.

USPTO Patent Application: Antibody Conjugates with Bis-MSPT Linker

The USPTO has published a new patent application (US20260083854A1) detailing antibody conjugates that utilize a bis-MSPT linker. The application, filed by inventors Riazul Alam, Guillermo S. Cortez, and Yan Wang, describes pharmaceutical compositions and methods related to these conjugates.

USPTO Patent Application: CD70 Antibody Drug Conjugates

The USPTO has published a new patent application (US20260083853A1) detailing CD70 antibody drug conjugates for treating cancer and autoimmune diseases. The application was filed on October 25, 2023, by inventors Xiao Shang and others.

USPTO Patent Application for Peptoid Nucleic Acid Delivery

The USPTO has published a patent application (US20260083769A1) detailing novel hydroxyalkyl-capped cationic peptoids for nucleic acid delivery. The application, filed by inventors from various institutions, describes compositions and methods for delivering polyanionic compounds to cells and eliciting immune responses.

Emergency Sirens Test Scheduled for April 7

The Delaware Division of Public Health announced a scheduled test of emergency sirens for Tuesday, April 7, 2026, at 7:20 PM. This test is part of the state's emergency preparedness measures, particularly concerning the Salem/Hope Creek Nuclear Generating Station.

MDE Approves Air Permit for Frederick Data Center

The Maryland Department of the Environment (MDE) has approved an air quality permit for Amazon Data Services, Inc. for emergency backup generators at a new data center campus in Frederick. The permit ensures generators will only be used during emergencies and includes continuous oversight under the Clean Air Act.